|Bid||25.75 x 2200|
|Ask||26.11 x 4000|
|Day's Range||25.91 - 26.00|
|52 Week Range||8.10 - 26.57|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.67|
NEW YORK , March 22, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amarin administered ...
NEW YORK, March 20, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Clementia Pharmaceuticals.
Does Clementia Pharmaceuticals (CMTA) have what it takes to be a top stock pick for momentum investors? Let's find out.
The interim order authorizes Clementia to call and hold on April 9, 2019 a special meeting of the holders of its common shares to approve the transaction. The transaction will require the approval of at least 66 2/3% of the votes cast by shareholders present in person or represented by proxy at the meeting as well as the approval of a majority of the votes cast by the Clementia's disinterested shareholders present in person or represented by proxy at the meeting. Clementia has set March 8, 2019 as the record date for the determination of the shareholders entitled to receive notice of and to vote at the meeting.
The interim order authorizes Clementia to call and hold on April 9, 2019 a special meeting of the holders of its common shares to approve the transaction. The transaction will require the approval of at least 66 2/3% of the votes cast by shareholders present in person or represented by proxy at the meeting as well as the approval of a majority of the votes cast by the Clementia's disinterested shareholders present in person or represented by proxy at the meeting.
NEW YORK, March 04, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
NEW YORK , March 1, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Clementia Pharmaceuticals, Inc. ("CMTA" ...
NEW YORK, Feb. 26, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 25) Abbott Laboratories (NYSE: ABT ) Arena Pharmaceuticals, ...
The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy. THE GLOBE AND MAIL ** Canada's biotech startup Clementia ...
Clementia Pharmaceuticals Inc. (CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the company will not report its fourth quarter and year end 2018 financial results on Feb. 28, 2019, and will cancel the associated conference call and its participation in the 2019 SVB Leerink Global Healthcare Conference. Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders and other diseases with high medical need.
Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Clementia Pharmaceuticals Inc. (CMTA) on behalf of stockholders concerning the proposed acquisition of the company by Ipsen S.A. Pursuant to the proposed transaction, announced on February 25, 2019 and valued at $1.31 billion, Clementia stockholders will receive $6.00 in cash for each share of Clementia common stock owned. The investigation focuses on whether Clementia and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
U.S. President Donald Trump's decision to delay an increase in tariffs on Chinese goods drove European shares to their highest since October with carmakers, most sensitive to the threat of a global trade war, leading the rally. The pan-European STOXX 600 closed up 0.3 percent and Germany's trade-sensitive DAX rose 0.4 percent. Italy's FTSE MIB outperformed the market, climbing 0.9 percent as government bonds jumped after Fitch affirmed the country's BBB credit rating.
NEW YORK, Feb. 25, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Clementia Pharmaceuticals Inc..
French healthcare company Ipsen agreed to buy Clementia Pharmaceuticals Inc. Ipsen said it would pay $25 a share in cash initially for Clementia, plus a contingent value right of $6 a share upon Food and Drug Administration approval of Clementia's palovarotene drug for the treatment of multiple osteochondromas, a rare bone disorder. The companies said the initial cash consideration represents a premium of 77% to Clementia's 30-day volume-weighted average stock price.
Swiss pharma giant Roche Holdings AG Basel ADR (OTC: RHHBY) announced early Monday a deal to buy U.S.-based gene therapy company Spark Therapeutics Inc (NASDAQ: ONCE) for $114.50 per share in cash, or a total equity value of $4.8 billion, including about $500 million of net cash expected at close. The per share value represents a 122.07-percent premium over Spark's Friday closing price of $51.56. Roche will commence a tender offer to acquire all outstanding shares of Spark, and upon completion will acquire the remaining untendered shares at the same price through a second step merger.
French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion (£1 billion), the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases. Ipsen's shares dipped 0.6 percent after the company said the takeover would initially weigh on margins due to the costs of forthcoming trials for Clementia products, but it hoped they would recover later on. Ipsen said it would buy all of Clementia's shares for $25 each in cash upfront and offer a contingent value right (CVR) purchase of $6.00 per share, giving a total transaction value of up to $1.31 billion.